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ABSTRACT 
Purpose: Local anaesthesia in eyelid surgery carries inherent risks, which has 
spurned ongoing investigation to identify needleless alternatives. 
Nanomedicines (particles ranging between 10nm and 1000nm in size) have 
shown promise in the transcutaneous delivery of certain drugs. In this study, 
we explore the feasibility of nano-enabled lidocaine delivery across an artificial 
skin analogue.  
Materials and Methods: Three different lidocaine-loaded nanocarriers were 
characterised. Diffusion studies were performed through cellulose membranes 
using customised Franz cells.  The nanocarriers included polymeric micelles 
(PM) (Soluplus), solid lipid nanoparticles (SLN) [Tripalmitin: Lecithin: Labrasol: 
polysorbate-20: water; 3.33:1:40:1:4.67 w/w] and Self-nanoemulsifying drug 
delivery systems (SNEDDS) [Capryol-90: Transcutol: Labrasol; 1:3:6 w/w]. 
Particles were characterised in terms of size, zeta-potential and morphology. 
One-way analysis of variance (ANOVA) with post hoc Tukey tests were used 
to assess differences in permeation at a significance of p<0.05. 
Results: Lidocaine loading was highest in SNEDDs (50 ± 2.1 mg g-1) compared 
with PMs (13.4 ± 0.6 mg ml-1) and SLNs (2.8±0.5 mg ml-1). All particles 
possessed a size below 150nm, illustrated good colloidal stability with a 
negative zeta-potential and a spherical morphology as demonstrated by 
transmission electron miscroscopy images. Cumulative lidocaine concentration 
after 6 hours was significant for both PMs (345.7+/-23.8 µg/cm2/h) and 
SNEDDS (224.8+/-118.2 µg/cm2/h) compared to SLNs (127.3+/-25.4 
µg/cm2/h). However, SLNs provided controlled release of lidocaine with a linear 
gradient that continued to increase up to 6 hours. 
Discussion: These results highlight the potential capability of nanoparticle 
lidocaine delivery in eyelid surgery. The achieved flux for all nanomedicines 
was higher than that reported for currently approved topical lidocaine 
formulations (including EMLA cream). 
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INTRODUCTION  
Local anaesthesia in eyelid surgery carries inherent risks such as 
haemorrhage, swelling, tissue distortion, obscuration of the surgical landmarks 
and needle phobia. This has spurned ongoing investigation to identify less 
invasive needleless alternatives for anaesthetic delivery [1].    
Local anaesthetics (LAs) work through the reversible inhibition of action 
potential generation and propagation with the pharmacological properties 
determined by their molecular structure (consisting of an aromatic ring 
(conferring lipophilicity and potency), an intermediate chain (determining 
stability) and an amine group [2 3]. Due to these properties, most LAs require a 
needle to bypass the skin barrier and provide effective dermal anesthesia.  
Transcutaneous delivery offers an alternative to injecting the LAs. The drug, 
however, has to be in a solubilized form, to allow passive diffusion through the 
skin, which is driven by a concentration gradient.  Of the most commonly used 
topical products for dermal anesthesia, EMLA cream (an 1:1 oil/water emulsion 
with the oily phase being an eutectic mixture of lidocaine 2.5% w/w and 
prilocaine 2.5%w/w cream) and Pliaglis [lidocaine (7% w/w) and tetracaine (7%) 
in a creamy vehicle that upon drying on exposure to air turns into a pliable, 
occlusive membrane] rely on eutectic mixtures of the aneasthetics to lower their 
melting point, hence solubilising the originally crystalline anesthetic drugs to 
allow for their incorporation within the formulation in high concentration and 
thus, enhancing their permeation across the skin [2 3]. Ametop gel, another 
popular topical product, uses xantham gum gel to suspend its anesthetic 
component, tetracaine [2 3]. The limitation of these products is, that lengthy 
application and dermal occlusion are needed to achieve maximal effect [2 3].  
Nanocarriers work in a fundamentally different way. By encapsulating the 
therapeutic drug, the resulting particles are of nano size range (between 10 to 
1000 nm), which is smaller than the original crystalline drug size while being 
are able to increase the aqueous solubility of the anaesthetics several fold [4]. 
Their increased surface area-to-volume ratio results in enhanced permeation 
via all routes across the skin including intracellular, intercellular and 
transappendageal [4]. There are several different categories of nanocarriers 
depending on the material used in the preparation (Figure 1). Polymeric 
micelles (PMs) are amphiphilic block co-polymers, which contain both 
hydrophilic and hydrophobic monomers that are able to self-assemble into 
nanoparticles which are stable in aqueous media.  They can solubilise 
substantial amounts of hydrophobic compounds in their inner core retaining 
high levels of structural stability [5 6]. Soluplus (polyvinyl caprolactam-polyvinyl 
acetate-polyethylene glycol graft co-polymer) is a generally regarded as safe 
(GRAS) polymer used to formulate PMs. Unlike the polymeric micelles, the self-
nanoemulsifying drug delivery systems (SNEDDS) are isotropic mixtures of 
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natural or synthetic oils, solid or liquid surfactants, or alternatively, one or more 
hydrophilic solvents and cosolvents/surfactants such as Labrasol 
(Caprylocaproyl macrogol-8 glyceride) and Transcutol (diethylene glycol 
monoethyl ether) that have the ability of forming fine oil-in-water (o/w) micro 
emulsions spontaneously or upon mild agitation when mixed with biological 
fluids [7]. Alternatively, lipidic nanomedicines prepared by solid lipids at room 
temperature, known as solid lipid nanoparticles (SLNs) have shown promise in 
delivery across the stratum corneum. SLNs can be composed by different type 
of solid lipids such as glycerides, waxes, and fatty acids, and stabilised by a 
wide range of surfactants in an aqueous media [8]. However, for all the above 
systems, critical properties for nanoparticulate drug delivery across the stratum 
corneum involve the size, surface charge, morphology of the particles as well 
as their drug loading efficiency. 
Lidocaine is the most commonly used LA in eyelid surgery due to its potency, 
rapid onset and moderate duration of action. In this work, we aim to explore the 
potential of these three different nanocarriers (PMs, SLNs and SNEDDs), as 
transcutaneous drug delivery systems for lidocaine, across an artificial skin 
barrier.  
MATERIALS AND METHODS: 
Source of Materials Used 
All chemicals and solvents were purchased from Sigma Aldrich (Dorset, UK). 
Excipients for SNEDDs [Labrasol (Caprylocaproyl macrogol-8 glycerides EP), 
Transcutol (diethylene glycol monoethyl ether EP) and Capryol 90 (Propylene 
glycol monocaprylate (type II) NF)] were donated by Gatefosse (Alpha 
Chemicals, Berkshire, UK), while phosphatidylcholine (soya lecithin) was 
donated by Lipoid AG (Lipoid S100, Lipoid AG, Steinhausen, Switzerland) and 
Soluplus (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft co-
polymer, 90-140 kDa) from BASF (Nottingham, UK).  The artificial skin 
(cellulose acetate membranes, Visking dialysis tubing, cut-off: 12-14KDa, 
thickness: 2 mm) was purchased from Medicell Membranes Ltd (London, UK). 
The Franz cells were custom made by Soham Scientific Ltd (Fordham, UK). 
Preparation of polymeric micelles (PMs) 
Lidocaine (20mg) and Soluplus (10mg) were dispersed in a phosphate buffer 
(10mM, 1mL) and then probe sonicated (15 minutes, 30% amplitude, Ultra 
Sonicator, UP200S, 200 Watt, Chesire, UK). The resulting suspension was 
centrifuged (8,000 rpm for 10 minutes, Juan B3i centrifuge, Fisher Scientific, 
Loughborough, UK) and the supernatant was isolated.  
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Preparation of solid lipid nanoparticles (SLNs) 
SLNs were prepared using a thin film hydration method followed by probe 
sonication [8]. Tripalmitin, phosphatidylcholine, and lidocaine (3 mg) were 
dissolved in a dichloromethane and methanol mixture (2:1 v/v) and rota-
evaporated until a thin film was produced (Rotavapor-R, Buchi, Flawil, 
Switzerland) at 50oC. The film was hydrated with 1% Tween 20 (polyethylene-
20-sorbitan monolaurate) solution and a 40% Labrasol aqueous suspension to 
a final composition lidocaine: tripalmitin: phosphatidylcholine: Tween 20: 
Labrasol: water of 0.8/3.33/1/40/1/53.87 w/w.  The resulting suspension was 
centrifuged (8,000 rpm for 10 minutes, Juan B3i centrifuge, Fisher Scientific, 
Loughborough, UK) and the supernatant was isolated for further testing. 
Preparation of Self Nanoemulsifying Drug Delivery Systems (SNEDDS) 
Solubility studies were carried out in water and other excipients to determine 
the maximum experimental solubility of lidocaine as it has not been previously 
reported. Excess lidocaine was dispersed in water, Capryol 90, Transcutol and 
Labrasol. The samples were left in a waterbath without shaking at 37oC for 24 
hours prior to centrifugation (12,000 rpm for 15 minutes, Juan B3i centrifuge, 
Fisher Scientific, Loughborough, UK) and the supernatant was isolated for 
further quantification using HPLC (as explained below).  
Ternary phase diagrams were constructed with surfactant (Labrasol), co-
surfactant (Transcutol (diethylene glycol monoethyl ether)), oil (Capryol 90) and 
water, using a water titration method [9]. A ratio of oil: co-surfactant of 1:6:3 
w/w/w was deemed optimal in terms of particle size and optical clarity of the 
resultant microemulsion type II.  
Particle size measurements 
All formulations were diluted with de-ionised water (1 to 100 v/v or 1 to 300 v/v) 
prior to particle size and zeta-potential measurements, which were performed 
using photon correlation spectroscopy (Malvern Zetasizer Nano-ZS, Malvern 
Instruments, Worcestershire, UK). The accuracy of the instrument was 
accessed periodically using a drop of latex beads (polystyrene, mean size: 
0.1µm, Sigma) in 50 mM sodium chloride. All measurements (n=15) were 
performed in triplicate.  
Transmission electron microscopy (TEM) Imaging  
A drop of the solution was placed on Formvar/Carbon Coated Grid (F196/100 
3.05 mm, Mesh 300, TAAB labs Ltd, England). Excess sample was filtered off 
and negatively stained with 2% freshly prepared aqueous uranyl acetate.  
Imaging was carried out under a Jeol JEM 1400 Transmission Electron 
Microscope (Hertfordshire, UK). Digital images were taken using an AMTV600 
(digital) camera.  
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In vitro Franz cells diffusion studies  
In vitro static diffusion cells are a validated and widely used method to evaluate 
skin permeability of newly developed formulations (Figure 2) [10 11]. Artificial 
membranes in conjunction with Franz-type diffusion studies are used to model 
human skin [10 11]. Modified Franz diffusion cells were specially made for this 
study. The cells displayed an approximate diffusional area of 0.07 cm2.  After 
the compartments were rinsed with an acetate buffer (20mM, pH 5) and a 
5x2mm stirrer bar was added to the receiver compartment, the compartment 
was filled up with 2mL of acetate buffer. The washed cellulose acetate 
membranes (MWCO: 12-14 kDa) were cut into square pieces (0.2 cm2) and 
mounted to adequately cover the receptor chambers. The donor compartment 
was placed on top of the receptor compartment covered with the cellulose 
membrane, tightly clamped and sealed with Parafilm to avoid leakage. The 
formulation (1mL or 1 g) was placed in the donor compartment, which was 
sealed with Parafilm and the Franz cells were submerged in a pre-heated 
waterbath (37oC, SBB Aqua 26 Plus, Grant, Shepreth, UK) with the stirrer (350 
rpm, MIX 15, 2MAG stirrer, Munchen, Germany).  Samples were taken at 0, 1, 
2, 4, 6 hours from the receiver compartment. Syringes were activated 5 times 
prior to sampling to ensure homogeneity (200 µL) and an equal volume of pre-
heated acetate buffer was replaced.  
High Performance Liquid Chromatography (HPLC) analysis 
Lidocaine concentration in the receiver fluid was determined from a standard 
calibration curve prepared from a lidocaine stock solution (10mg mL-1 in 
dimethylsulfoxide) that was diluted with an acetate buffer (pH 5.0) to elicit a 
linear calibration curve (1 -100 µg mL-1). Two Phenomenex Onyx Monolithic 
C18 columns attached to a guard column (20+100+100 mm x 4.6 mm, 5µm) 
were maintained at 25oC for analysis using an Agilent 1100 HPLC.  Samples 
(40µL) were eluted at 1.2mL min-1 using a gradient method. The mobile phase 
consisted of an acetate buffer (20mM, pH 5 ± 0.1) and acetonitrile and detection 
was performed at 220 and 254 nm. The gradient method expressed as time 
(min): acetonitrile % was as follows: 0:5, 5:10, 10:20, and 20:30, with a retention 
time of 22.1 minutes. For each of the combinations a minimum of three cellulose 
membranes and three iterations of HPLC were done. 
Data analysis and statistical analysis 
Microsoft Office Excel 2007 (Microsoft corporation, Seattle, USA) was used to 
analyse all data, calculate standard deviations, and fit linear equations. One-
way analysis of variance (ANOVA) with post hoc Tukey test was used to assess 
differences in permeation across cellulose membranes, where p<0.05 was 
considered statistically significant using Minitab 17 (Minitab Ltd, Coventry, UK).  
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RESULTS: 
The characteristics of all three nanomedicines are summarised in Table 1. 
Lidocaine SNEDDS illustrated the highest loading (50 ± 2.1 mg g-1) from all 
nanomedicines followed by polymeric micelles (13.4 ± 0.6 mg mL-1) and SLNs 
(2.8 ± 0.5 mg mL-1). This is likely to be attributed to the high solubility of 
lidocaine within the selected excipients (Figure 3). All nanoparticulate 
formulations possessed a particle size below 150 nm and an anionic charge in 
excess of -10mV illustrating acceptable colloidal stability and spherical or 
quasispherical morphology (Tables 1, Figure 4B-4D). The cumulative release 
of the lidocaine-loaded nanomedicines over a 6-hour period is reported in Table 
2.   SNEDDS and polymeric micelles illustrated superior flux (277 and 193 
µg/cm2/h) across cellulose membrane compared to SLNs (86 µg/cm2/h). 
 
Table 1: Characteristics of Lidocaine-loaded nanocarriers (Values are 
presented with their standard deviation) 
Nanomedicine  Polymeric Micelles 
(PM) 
Solid Lipid Nanoparticles 
(SLNs) 
Self-nanoemulsifying drug 
delivery systems (SNEDDS) 
Appearance  
 
  
 
Maximum Lidocaine 
Loading (mg mL-1) 
13.4 ± 0.6 2.8 ± 0.5 50 ± 2.1 
Particle size (nm) 91 ±1 104 ± 1 103 ± 23 
Colloidal Stability  
(zeta-potential, mV) 
Weakly stable 
 
-9.8 ± 2.5 
Stable 
- 23.8 ± 0.4 
Very Stable 
- 77.6 ± 0.6 
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Table 2: Concentration of Lidocaine-loaded nanocarriers over time across 
cellulose acetate membrane in Franz cell diffusion studies  
 
Time (h) 
 
Polymeric Micelles    
(10mg mL-1) 
SLNs                                 
(2mg mL-1) 
SNEDDs                                  
(50mg g-1) 
Concentration 
(μg ml-1) 
SD Concentration 
(μg ml-1) 
SD Concentration 
(μg ml-1) 
SD 
0 0 0 0 0 0 0 
1 88.3 21.7 6.9 8.7 46.4 41.2 
2 221.9 28.6 32.6 12.0 200.0 72.8 
4 351.9 27.2 80.5 14.0 268.9 145.8 
6 345.7 23.8 127.3 25.4 224.8 118.2 
 
 
DISCUSSION:  
In this study, three different types of nanomedicines (lipidic nanoparticles, 
polymeric nanoparticles and microemulsions), all prepared using safe (GRAS) 
excipients, were compared for permeation across artificial skin under sink 
conditions. We show that nano-enabled formulations with high loading of 
lidocaine can be successfully formulated showing potential in carrying the 
anaesthetic across an artificial skin barrier. Lidocaine SNEDDS illustrated apart 
from high colloidal stability, the highest loading (50 ± 2.1 mg g-1) compared to 
other nanomedicines which is almost 18 fold higher than lidocaine aqueous 
solubility followed by polymeric micelles and SLNs (Table 1). All prepared 
particles indicated a nanoparticulate size below 150 nm and spherical or quasi-
spherical morphology (Table 1).  
The diffusion studies results (Figure 4A) indicate that SNEDDS and polymeric 
micelles result in permeation with a short lag time and achieving significant 
concentrations in the receptor compartment within the first hour. SLNs, on the 
other hand, provided controlled release of lidocaine but with a linear gradient 
that continued to increase up to 6 hours. The achieved flux for all 
nanomedicines is higher than that experimentally identified across eyelid skin 
in our setting (65.68 µg/cm2/h, data not shown) and that reported for EMLA 
cream tested in skin (73.81 µg/cm2/h for lidocaine hydrochloride and 53.93 
µg/cm2/h for prilocaine hydrochloride)[12]. Polymeric micelles permeation across 
cellulose acetate membranes [that lack a formidable lipidic barrier posed by the 
anucleate corneocytes of the stratum corneum] may be favoured. However, this 
would not necessarily hinder the release of the nanoemulsion or solid lipid 
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nanoparticles as they have been shown to be able to permeate the stratum 
corneum due to their lipidic nature [13 14].  
Active pharmaceutical ingredients (APIs) must be in the solubilised state to 
penetrate the stratum corneum via a passive transport mechanism driven by 
the concentration gradient between the formulation and the skin. The selection 
of the oil phase and surfactant in this study was based on the high solubility of 
lidocaine within these excipients (Figure 3) which is higher than other 
commonly used penetration enhancers such as isopropyl myristate and 
isopropyl palmitate (131 and 110 mg mL-1 respectively) which are used in 
commercially available organogels for local delivery of lidocaine [15]. 
Transcutol was added to the formulation as it enables high drug loading and 
the generation of a steep concentration gradient. Transcutol also disorganises 
the intercellular space between corneocytes which would facilitate diffusion in 
actual skin. Additionally, the ease of manufacture and scale-up is one of the 
most important advantages that make SNEDDS unique compared to other 
novel drug delivery systems, such as liposomes and nanoparticles.  
To our knowledge, no studies have been conducted to explore the potential of 
nanomedicines for eyelid surgery. The results presented here demonstrate 
promising characteristics (particle size, stability and loading efficiency) for three 
categories of nanoparticles in the delivery of lidocaine across an artificial skin 
analogue. Further experiments are under way to ascertain the behaviour of 
these lidocaine-loaded nanomedicines across human skin tissue and their long-
term safety before broader application can be considered. 
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FIGURE LEGENDS: 
Figure 1. Permeation pathways for local anaesthetics and local anaesthetic 
loaded nanomedicines across the skin; nanomedicines utilise apart from the 
intercellular and trancellular route also the shunt routes (transfollicular, 
transglandular).   
Figure 2. Preparation of Franz Cells for diffusion studies; A: Schematic diagram 
of Franz cells compartments, B: Specially prepared Franz cells for use with 
small surface narrow samples, C: Sampling at various time points from Franz 
cells, D-F: Step by step preparation of Franz cells for diffusion studies.  
Figure 3. Solubility studies of Lidocaine at various generally regarded as safe 
(GRAS) excipients.  
Figure 4. A: Cumulative release of the three Lidocaine-loaded nanocarriers 
across cellulose membrane in Franz cell diffusion studies; Lidocaine-loaded 
PMs (triangles), Lidocaine-loaded SNEDDs (squares) and Lidocaine-loaded 
SLNs (circles). Transmission electron microscopy (TEM) images of aqueous 
dispersions of (B) Lidocaine-loaded PMs (10 mg mL-1), (C) Lidocaine-loaded 
SNEDDS (50mg g-1) and (D) Lidocaine-loaded SLNs (2.8mg mL-1). Staining: 
1% Uranyl Acetate, Bar: 100nm.  
 
 
 
 
 
 
 
 
  
 
 
 
